Gain Therapeutics Presents Positive Clinical Data for Rexaceract in Parkinson's Disease Phase 1b Study
Rapid Read

Gain Therapeutics Presents Positive Clinical Data for Rexaceract in Parkinson's Disease Phase 1b Study

What's Happening? Gain Therapeutics, Inc. (Nasdaq: GANX) announced positive clinical data from its Phase 1b study of rexaceract (formerly GT-02287) for Parkinson's disease (PD) at the 31st IAPRD World Congress. The data showed that MDS-UPDRS motor scores remained stable over 12 months of daily oral
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.